These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3367489)

  • 1. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
    Paul TL; Kerrigan J; Kelly AM; Braverman LE; Baran DT
    JAMA; 1988 Jun; 259(21):3137-41. PubMed ID: 3367489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
    Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
    Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in postmenopausal women treated with L-thyroxine.
    Adlin EV; Maurer AH; Marks AD; Channick BJ
    Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA; Betteridge J; Holder R; Sheppard MC
    Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
    Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
    J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine.
    Kung AW; Pun KK
    JAMA; 1991 May 22-29; 265(20):2688-91. PubMed ID: 2023349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
    Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urinary excretion of sulfated 3,3',5-triiodothyronine in patients with nodular goiters receiving suppressive thyroxine therapy.
    Huang WS; Kuo SW; Chen WL; Fuh MM; Wu SY
    Thyroid; 1996 Apr; 6(2):91-6. PubMed ID: 8733878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
    Kung AW; Lorentz T; Tam SC
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
    De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
    Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW; Yeung SS
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term thyroxine treatment and bone mineral density.
    Franklyn JA; Betteridge J; Daykin J; Holder R; Oates GD; Parle JV; Lilley J; Heath DA; Sheppard MC
    Lancet; 1992 Jul; 340(8810):9-13. PubMed ID: 1351654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.